involve facial morphology and alter the functioning of jaw muscles that carries both diagnostic and therapeutic implications.
The histopathological sections were examined for various corneal dystrophies
1] Within these genetic disorders, muscular dystrophies
(MDs) are a broad group of muscle illness, which affect humans as well as animals.
Initially, the companies will focus on Becker and Duchenne muscular dystrophies
, in addition to myotonic dystrophy.
A new international classification of the corneal dystrophies
has been developed which takes into account the chromosomal loci of the various dystrophies
, as well as the responsible genes and their mutations.
are genetic disorders primarily affecting skeletal muscle that result in greatly impaired mobility and, in severe cases, respiratory and cardiac dysfunction.
Seven contributions address the following topics: IC3D classification of corneal dystrophies
, clinical landmarks, histological landmarks, genetics, differential diagnosis of Schnyder corneal dystrophy, clinical and basic aspects of gelatinous drop-like corneal dystrophy, and stage-related therapy.
Introduction: Muscular dystrophies
(MD) traditionally refer to a group of genetically determined, progressive, degenerative disorders of the skeletal muscle.
Muscle biopsy with proper immunohistochemistry (IHC) is the gold -standard to distinguish muscular dystrophies
(deadly degenerative disorders).
are very rare, but an estimated 30,000 people in the UK are affected.
The editors have brought together various molecular methods for the clinical analysis of many of the muscular dystrophies
While the strategy of transplanting muscle cells into people with muscular dystrophies
or other muscle diseases makes sense in theory, it has not lived up to its promise.
Since 1986, scientists have identified genes that, when flawed, can cause myotonic, Duchenne, Becker, limb-girdle (some forms), congenital (one form) and Emery-Dreifuss muscular dystrophies
Different genetic alterations cause different types of muscular dystrophies
24 August 2011 - Swiss specialty pharmaceutical company Santhera Pharmaceuticals (VTX:SANN) said today that the US Patent and Trademark Office has granted patent protection for the use of idebenone (brand name Catena) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies